Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms

BACKGROUND AND PURPOSE: Anti-CD20 monoclonal antibodies (MoAbs), rituximab (RIT), and obinutuzumab (OBZ) are the central components of immunochemotherapy for B-cell lymphoma (BCL). However, these agents potentially cause B-cell depletion, resulting in the impairment of antibody (Ab) production. Duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Onishi, Akio, Matsumura-Kimoto, Yayoi, Mizutani, Shinsuke, Tsukamoto, Taku, Fujino, Takahiro, Miyashita, Akihiro, Nishiyama, Daichi, Shimura, Kazuho, Kaneko, Hiroto, Kawata, Eri, Takahashi, Ryoichi, Kobayashi, Tsutomu, Uchiyama, Hitoji, Uoshima, Nobuhiko, Nukui, Yoko, Shimura, Yuji, Inaba, Tohru, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884434/
https://www.ncbi.nlm.nih.gov/pubmed/36721633
http://dx.doi.org/10.2147/IDR.S396271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884434/
https://www.ncbi.nlm.nih.gov/pubmed/36721633
http://dx.doi.org/10.2147/IDR.S396271

Ejemplares similares